A Phase III Randomized Controlled Trial Evaluating the Efficacy and Safety of Tofacitinib Combined With Imatinib in Patients With Moderate-to-Severe Palmoplantar Pustulosis

Inclusion Criteria: \- Participants aged ≥ 18 years. Diagnosis of PPP for at least 12 weeks prior to screening. PPPASI ≥ 12 at screening and baseline. PPP-IGA ≥ 3 at screening and baseline. Presence of pustules on palms and/or soles at screening and baseline. Confirmed diagnosis of PPP by photographic adjudication. Exclusion Criteria: * Significant improvement of PPP symptoms between screening and baseline (PPPASI decrease ≥ 5). Presence of other forms of psoriasis or inflammatory skin diseases. Active infection or history of serious infection within specified timeframes. Positive for hepatitis B, hepatitis C, or HIV. Active or latent tuberculosis. History of malignancy within 5 years (except certain skin cancers). Laboratory abnormalities meeting exclusion criteria (e.g., ALT/AST ≥ 3×ULN, ANC \< 1.5×10³/μL, etc.).